tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinom, ne-malih stanica pluća - antineoplastična sredstva - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
tabrecta 150mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - kapmatinib - film tableta - 150mg
tabrecta 200mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - kapmatinib - film tableta - 200mg